Drug
Etelcalcetide clinical trials
Also written AMG 416, Parsabiv™ and KAI-4169.
- studies test it
- 19
- open now
- 2
- in phase 3
- 9
- first study started
- 2010
Keep track of what changes. Save the etelcalcetide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 2 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 5
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 2
Amgen (12) · KAI Pharmaceuticals (5) · Thomas Nickolas, MD MS (1) · Prim. Priv. Doz. Dr. Daniel Cejka (1)
Studies
Open first, then newest update. How each study uses etelcalcetide is read from its arms, and is right about nine times in ten.
Testing it · 19
- A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving HemodialysisRecruitingPhase 3AmgenNCT03969329Written as Etelcalcetide
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisRecruitingPhase 3AmgenNCT03633708Written as Etelcalcetide
- The Effect of Etelcalcetide on CKD-MBDCompletedPhase 2Thomas Nickolas, MD MSNCT03960437Written as Etelcalcetide
- A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis PatientsCompletedPhase 2Prim. Priv. Doz. Dr. Daniel CejkaNCT03795558Written as Etelcalcetide
- Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)CompletedPhase 3AmgenNCT03299244Written as Etelcalcetide
- A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416CompletedPhase 1AmgenNCT03283098Written as Etelcalcetide
- Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on HemodialysisCompletedPhase 3AmgenNCT01785849Written as Etelcalcetide
- Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedPhase 3AmgenNCT01788046Written as Etelcalcetide
- Head-to-Head Study of Etelcalcetide (AMG 416) and CinacalcetCompletedPhase 3AmgenNCT01896232Written as Etelcalcetide
- A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving HaemodialysisCompletedPhase 1AmgenNCT02833857Written as Etelcalcetide
- Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedPhase 3AmgenNCT01785875Written as Etelcalcetide
- Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to EtelcalcetideCompletedPhase 3AmgenNCT01932970Written as Etelcalcetide
- Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving DialysisCompletedPhase 1AmgenNCT02054572Written as [¹⁴C]Etelcalcetide
- Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary HyperparathyroidismCompletedPhase 1KAI PharmaceuticalsNCT01134562Written as Etelcalcetide
- Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on HemodialysisCompletedPhase 3AmgenNCT02102204Written as Etelcalcetide
- Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male VolunteersCompletedPhase 1KAI PharmaceuticalsNCT01134549Written as Etelcalcetide
- Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary HyperparathyroidismCompletedPhase 2KAI PharmaceuticalsNCT01254565Written as Etelcalcetide
- Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary HyperparathyroidismTerminatedPhase 2KAI PharmaceuticalsNCT01576146Written as Etelcalcetide
- Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone DisorderCompletedPhase 2KAI PharmaceuticalsNCT01414114Written as Etelcalcetide
As the comparator · 1 — what is tested is compared with etelcalcetide
Codes
What other systems call etelcalcetide · ClinicalTrials.gg INT006350
- MeSH (NLM) C583569etelcalcetide hydrochlorideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 60ME133FJBETELCALCETIDEConfirmed FDA, Wikidata
- RxNorm 1876119Confirmed FDA, Wikidata
- Wikidata Q21098973etelcalcetideConfirmed FDA, Wikidata
- NCI Thesaurus C129712EtelcalcetideConfirmed FDA, Wikidata
- DrugBank DB12865One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583569 | etelcalcetide hydrochloride | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 60ME133FJB | ETELCALCETIDE | Confirmed FDA, Wikidata |
| RxNorm | 1876119 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21098973 | etelcalcetide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C129712 | Etelcalcetide | Confirmed FDA, Wikidata |
| DrugBank | DB12865 | — | One source Wikidata |
Also registered as etelcalcetide hydrochloride (UNII 72PT5993DU · RxNorm 1876122).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.